The frequency of unwanted reactions is given in accordance with the WHO classification: "very frequent" - 1/10, "frequent" - more than 1/100, but less than 1/10, "infrequent" - more than 1/1000, but less than 1/100, "rare" - more than 1/10000, but less than 1/1000 and "very rare" with a occurrence of less than 1/10000, including individual messages.
In the application of Reaferon-EU (in clinical studies and outside clinical studies), the following adverse events were observed:
Often with parenteral administration of the drug, there is a flu-like syndrome (chills, fever, asthenia, fatigue, fatigue, myalgia, arthralgia, headaches), partially docked with paracetamol, indomethacin. As a rule, the flu-like syndrome manifests itself at the beginning of treatment and decreases with the continuation.
From the cardiovascular system: rarely - arrhythmias, transient reversible cardiomyopathy, very rarely - arterial hypotension, myocardial infarction.
From the digestive system: rarely - dry mouth, nausea, abdominal pain, dyspepsia, eating disorders, weight loss, vomiting, diarrhea, very rarely - pancreatitis, hepatotoxicity.
From the central nervous system: rarely - irritability, nervousness, depression, asthenia, insomnia, anxiety, impaired ability to concentrate, suicidal thoughts, aggressiveness, very rarely - neuropathies, psychosis.
From the skin: rarely - skin rashes and itching, increased sweating, hair loss. When injected into the focus or under the lesion, a local inflammatory reaction is rare. These side effects are usually not an obstacle to continued use of the drug.
From the endocrine system: on the background of long-term use of the drug, there may be changes in the thyroid gland. Very rarely - diabetes mellitus.
From the laboratory indicators: when the drug is used, there may be deviations from the norm of laboratory indicators, manifested by leukopenia, lymphopenia, thrombocytopenia, anemia, increased activity of alanine aminotransferase, alkaline phosphatase, creatinine concentration, urea. Typically, these changes are usually minor, asymptomatic and reversible.
From the musculoskeletal system: rarely - rhabdomyolysis, leg cramps, back pain, myositis, myalgia.
From the respiratory system: rarely - pharyngitis, cough, dyspnea, pneumonia.
From the urinary system: very rarely - kidney failure.
From the immune system: rarely - autoimmune pathology (vasculitis, rheumatoid arthritis,lupus-like syndrome), very rarely - sarcoidosis, angioedema, allergic edema, anaphylaxis, facial edema.
On the part of the organs of vision: with topical application of the drug on the mucous membrane of the eye, there may be hyperemia, single follicles, edema of the conjunctiva of the lower arch. Rarely - hemorrhages in the retina, focal changes in the fundus, thrombosis of the arteries and veins of the retina, decreased visual acuity, optic neuritis, edema of the optic nerve.
From the organs of hearing: rarely - hearing impairment.
With severe local and general adverse reactions, the drug should be discontinued.